The semaglutide cohort ( n = 1470) compared with the non-GLP-1RA anti-obesity medications cohort ( n = 2784) was older, included more women, had a higher prevalence of severe obesity and obesity-associated comorbidities including T2DM and lower prevalence of adverse socioeconomic determinants of health, mental disorders, and substance use disorders
For example, if your protocol calls for 250mcg daily for 30 days, and you reconstituted with 2 mL of bacteriostatic water, each 0.1 mL withdrawal contains a specific amount
A direct head-to-head trial is underway (with initial results due later in 2026), and current data shows that when the highest dose of each drug is taken over a 72-week period, those on tirzepatide returned a higher percentage of total body weight loss (20.2% - 21.1% as opposed to 13.7% - 14.1% for semaglutide (as detailed in the New England Journal of Medicine Study of May 2025)
Understanding these factors is crucial for any researcher
The list price as of April 2026 varies by compound and formulation
